/l) and splenomegaly. The karyotype was normal, but reverse transcription-PCR with primers covering the juxtamembrane and tyrosine kinase domains of platelet-derived growth factor receptor A (PDGFRA) (exons 11-18) and subsequent sequence analysis identified a C4T change that predicts a T674I mutation in the ATP-binding region of PDGFRA (PDGFRA T674I ). Including the case presented here, seven cases of secondary resistance to imatinib have now been reported in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. [1] [2] [3] [4] [5] [6] [7] We analyzed the clinical and molecular characteristics from four patients with a T674I mutation, 1, 3, 5, 7 one patient with a D842V mutation 6 and one patient with a T674I mutation, followed by a D842V mutation (Table 1) . 4 All patients were male, the median age at diagnosis was 39 years (range 25-67). Imatinib had been administered at doses of 100 mg every other day (1/5), 100 mg/day (2/5) or 400 mg/day (2/5); in two cases, the dose of imatinib had been not reported. The median time to imatinib resistance was 5 months (range 2-9). Marrow blasts were increased in five of seven patients, suggesting accelerated/blast phase. Four patients died, three of them within 5 months after diagnosis of secondary resistance to imatinib (time interval was not reported in the fourth patient). 3, 4, 6, 7 The cases above indicate that secondary resistance is rare, but it is also notable that only two different mutations (T674I, D842V) have yet been identified. towards second-generation tyrosine kinase inhibitors, we treated our patient with nilotinib 400 mg twice a day. However, no response was observed within 4 weeks of treatment and in fact, eosinophil numbers increased. We therefore switched to sorafenib 400 mg twice a day. Similar to nilotinib, there were no signs of response within 2 months of treatment (stable disease). Of interest, a second patient treated with sorafenib only showed a short-lived clinical response (3 months) due to the rapid emergence of a D842V mutant. 4 Meanwhile, a brother of our patient was identified as a fully HLA-identical sibling stem cell donor. Allogeneic stem cell transplantation was performed 5 months after first detection of imatinib-resistance. The conditioning regimen was a modified FLAMSA-RIC protocol, consisting of fludarabine 30 mg/m 2 , high-dose cytarabine 2 g/m 2 , and amsacrine 100 mg/m 2 from days À14 to À11, busulvex 3.2 mg from days À7 to À5, and anti-thymocyte globin (ATG) total 30 mg/kg fractionated from day À4 to À1. Posttransplant, he developed steroid-responsive grade II graftversus-host-disease of the skin and subsequently limited chronic graft-versus-host-disease. Complete hematopoietic chimerism was achieved 4 months after transplant. At the time of reporting ( þ 392 days), the patient is well and in complete hematologic and molecular remission.
Nilotinib, sorafenib and midostaurin demonstrated excellent activity at nanomolar concentrations towards PDGFRA T674I in cell lines, transfected cells and in mouse models. The lack of clinical activity of two of these drugs in a patient with PDGFRA T674I raises concerns regarding (i) additional molecular abnormalities conferring resistance independent of the underlying point mutation or (ii) other unknown factors that are contributing to potentially misleading results from in vitro studies. In this respect, it should be noted that the situation is similar to the KIT D816V mutation in patients with systemic mastocytosis. Nilotinib, dasatinib and midostaurin have been shown to suppress the malignant clone in cells and mice at therapeutic concentrations. However, only midostaurin, but not nilotinib or dasatinib, have yet shown adequate clinical activity. The activity regarding hematological and molecular remissions of Janus kinase inhibitors in JAK2 V617F positive myeloproliferative neoplasms is also clearly inferior to what we would have expected from in vitro experiments.
Letters to the Editor Abbreviations: CP, chronic phase; CEL, chronic eosinophilic leukemia; BP, blast phase; SCT, stem cell transplantation; BID, twice a day; BM, bone marrow; n.a., not available.
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Treatment with imatinib is associated with an excellent prognosis in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia in first chronic phase. Secondary resistance is rather rare, but occurs predominantly within the first year of diagnosis. Resistance is associated with PDGFRA kinase domain mutations that are sensitive in vitro to second-generation tyrosine kinase inhibitors, but these compounds seem to have limited activity in clinical practice. Because of an aggressive clinical course and lack of alternative conventional treatment options, allogeneic stem cell transplantation should be performed in eligible patients, as it might be the only effective and curative treatment option. New stem cell meeting on the Baltic Sea is launched Leukemia (2012) 26, 164-166; doi:10.1038 /leu.2011 published online 19 July 2011 The Baltic Sea, which connects middle, northern and eastern European countries, is the setting for an exciting new stem cell conference, the Baltic Stem Cell Meeting. Cold in winter, but glorious in summer, the Baltic coast will be the place where, every 2 years, researchers from all over the world, possessed by the fever of stem cell research, will come together. Besides the pleasant summer temperature, it is no coincidence that stem cell research in this part of world has a long history. It was in St Petersburg that Alexander Maximow first coined the term 'stem cell'. After demonstrating that all blood cells develop from a common precursor cell, Maximow proposed the unitarian theory of hematopoiesis. His experimental work provided evidence, confirming that lymphocytes of the blood and lymph nodes are undifferentiated cells with stem cell properties. 1 A few decades earlier, at the opposite side of the Baltic in western Pomerania (at that time part of Prussia), Rudolf Virchow, the father of cellular pathology, was born. He is also cited as the first pathologist to recognize leukemia cells and proposed the famous epigram 'Omnis cellula e cellula' (every cell originates from a similar existing cell). He and his trainee, Julius Cohnheim, who was also born close to the Baltic coast in western Pomerania, proposed the embryonic rest hypothesis of cancer development, a concept that laid the groundwork for the currently popular theory in which cancer is described as a stem cell disorder.
2 In more modern times, other excellent stem cell researchers, including Dr Sven Age Killmann (a founder of our journal Leukemia), have also worked in the Baltic region in Copenhagen. Dr Killmann, together with his wife (Dr Nicole Killmann, editor of Leukemia), coined the sleeper-feeder theory for leukemia. Accordingly, it has been proposed that malignancies in the hematopoietic system seem to depend on a small subset of so-called cancer stem cells for their continued growth and progression.
This first Baltic Stem Cell Meeting was held in Szczecin, the capital of Western Pomerania, Poland, and was sponsored by an economic innovation grant awarded by the European Union and supported by the Polish Ministry of Science. The host of the meeting was Pomeranian Medical University.
Nearly 50 lectures were presented by top stem cell researchers from nearly every continent. The major scientific topics of this meeting were clinical applications of adult
